2. Academic Validation
  3. Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance

Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance

  • Bioorg Med Chem Lett. 2012 Nov 1;22(21):6671-6. doi: 10.1016/j.bmcl.2012.08.102.
Fabrizio Giordanetto 1,  Andreas Wållberg,  Saswati Ghosal,  Tommy Iliefski,  Johan Cassel,  Zhong-Qing Yuan,  Henrik von Wachenfeldt,  Søren M Andersen,  Tord Inghardt,  Anders Tunek,  Sven Nylander
Affiliations

Affiliation

  • 1 Medicinal Chemistry, AstraZeneca R&D, CVGI iMed, Pepparedsleden 1, SE-431 83 Mölndal, Sweden. fabrizio.giordanetto@astrazeneca.com
PMID: 23010262 DOI: 10.1016/j.bmcl.2012.08.102
Abstract

Structure-based evolution of the original fragment leads resulted in the identification of 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, (S)-21, a potent, selective phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor with favourable in vivo antiplatelet effect. Despite its antiplatelet action, (S)-21 did not significantly increase bleeding time in dogs. Additionally, due to its enhanced selectivity over p110α, (S)-21 did not induce any Insulin resistance in rats.

Figures